




PHARMACEUTICAL 2019

Fibrocell Science Inc.
Rank 214 of 363





PHARMACEUTICAL 2019

Fibrocell Science Inc.
Rank 214 of 363

The relative strengths and weaknesses of Fibrocell Science Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fibrocell Science Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Fibrocell Science Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 20% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	14,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,172
Liabilities, Non-Current	0
Other Assets	1.0
Other Compr. Net Income	0
Other Expenses	737
Other Liabilities	4,029
Other Net Income	2,921
Other Revenues	0
Property and Equipment	1,222
Research and Development	6,018
Selling, General and Administrative Expense	6,405

Output Variable	Value in 1000 USD
Assets	15,758
Liabilities	6,201
Expenses	13,160
Revenues	0
Stockholders Equity	9,557
Net Income	-10,239
Comprehensive Net Income	-10,239
Economic Capital Ratio	56%